title: [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
abstract: OBJECTIVE
  Clinical trials have shown that combining beta-blockers and angiotensin-converting enzyme (ACE) inhibitors has an additive effect in reducing mortality in patients with left ventricular dysfunction following acute myocardial infarction. Whether this additive effect also occurs in unselected post-myocardial infarction patients is unknown.
  
  
  METHODS
  In total, 5397 patients who were discharged from hospital after suffering an acute myocardial infarction were followed for 1 year. The primary endpoint was all-cause mortality. The effects of the medications on 1-year survival were analyzed using a Cox regression model, which included propensity scores for beta-blocker and ACE inhibitor use to take account of any potential imbalance in drug prescription rates.
  
  
  RESULTS
  At hospital discharge, 55.9% of patients were receiving beta-blockers and 45.1%, ACE inhibitors. The 1-year mortality rate was 5.5%. Overall, combination of the two medications significantly reduced the 1-year mortality rate (hazard ratio [HR]=0.51; 95% confidence interval [IC], 0.32-0.82); P<.005) to a greater extent than ACE inhibitors alone (HR=0.78; 95% CI, 0.54-1.12; P=.2) or beta-blockers alone (HR=0.67; 95% CI, 0.43-1.05; P=.08). The same trend was also observed in low-risk patients without acute heart failure who had an ejection fraction > or =40%.
  
  
  CONCLUSIONS
  In unselected post-myocardial infarction patients, combined prescription of beta-blockers and ACE inhibitors had an additive effect on the 1-year survival rate.
authors.affiliation: Area de Cardiología y Críticos, Hospital Txagorritxu, Vitoria, Spain. aborau@secardiologia.es
authors.forename: Fernando
authors.initials: F
authors.lastname: Arós
authors.forename: Angel
authors.initials: A
authors.lastname: Loma-Osorio
authors.forename: Joan
authors.initials: J
authors.lastname: Vila
authors.forename: Lorenzo
authors.initials: L
authors.lastname: López-Bescós
authors.forename: José
authors.initials: J
authors.lastname: Cuñat
authors.forename: Emilio
authors.initials: E
authors.lastname: Rodríguez
authors.forename: José M
authors.initials: JM
authors.lastname: San José
authors.forename: Magda
authors.initials: M
authors.lastname: Heras
authors.forename: Jaume
authors.initials: J
authors.lastname: Marrugat
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality*; D012042:Registries; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors